Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease Feb 9, 2026 07:28AM
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide Dec 16, 2025 07:40AM
Arch Biopartners closes $600,000 private placement Nov 19, 2025 04:28PM
Arch Biopartners Closes Non-Brokered Private Placement Nov 19, 2025 04:27PM
Arch Biopartners arranges $500,000 private placement with company officer Nov 10, 2025 08:10AM


Nov 10, 2025 08:10AM Arch Biopartners Arranges Non-Brokered Private Placement
Nov 5, 2025 08:30AM Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia